Randi Y Leavitt
Overview
Explore the profile of Randi Y Leavitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marty F, Ljungman P, Chemaly R, Wan H, Teal V, Butterton J, et al.
Am J Transplant
. 2019 Dec;
20(6):1703-1711.
PMID: 31883426
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind,...
2.
Ljungman P, Schmitt M, Marty F, Maertens J, Chemaly R, Kartsonis N, et al.
Clin Infect Dis
. 2019 Jun;
70(8):1525-1533.
PMID: 31179485
Background: In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This...
3.
Marty F, Ljungman P, Chemaly R, Maertens J, Dadwal S, Duarte R, et al.
N Engl J Med
. 2017 Dec;
377(25):2433-2444.
PMID: 29211658
Background: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. Methods: In this phase 3, double-blind trial, we...
4.
Squires K, Bekker L, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers A, et al.
Open Forum Infect Dis
. 2017 May;
4(1):ofw047.
PMID: 28480227
Background: Antiretroviral therapy in human immunodeficiency virus (HIV)-infected women and blacks merits particular scrutiny because these groups have been underrepresented in clinical trials. Methods: To document the effects of raltegravir...
5.
Ofotokun I, Na L, Landovitz R, Ribaudo H, McComsey G, Godfrey C, et al.
Clin Infect Dis
. 2015 Mar;
60(12):1842-51.
PMID: 25767256
Background: Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and...
6.
Quirk E, Brown E, Leavitt R, Mogg R, Mehrotra D, Evans R, et al.
Open Forum Infect Dis
. 2015 Mar;
1(1):ofu016.
PMID: 25734089
The immunogenicity results from 3 phase I trials of the Merck DNA human immunodeficiency virus (HIV) vaccine have previously been reported. Because preventive DNA vaccine strategies continue to be leveraged...
7.
Lennox J, Landovitz R, Ribaudo H, Ofotokun I, Na L, Godfrey C, et al.
Ann Intern Med
. 2014 Oct;
161(7):461-71.
PMID: 25285539
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. Objective: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for...
8.
Rockstroh J, Teppler H, Zhao J, Sklar P, Miller M, Harvey C, et al.
AIDS
. 2011 Apr;
25(11):1365-9.
PMID: 21522004
Objective: We evaluated the long-term efficacy of raltegravir according to HIV-1 subtype (B and non-B) using data from three phase III studies in treatment-experienced (BENCHMRK-1 and 2) and treatment-naive (STARTMRK)...
9.
Nguyen B, Isaacs R, Teppler H, Leavitt R, Sklar P, Iwamoto M, et al.
Ann N Y Acad Sci
. 2011 Mar;
1222:83-9.
PMID: 21434946
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety...
10.
Teppler H, Brown D, Leavitt R, Sklar P, Wan H, Xu X, et al.
Curr HIV Res
. 2011 Jan;
9(1):40-53.
PMID: 21198432
Background: Raltegravir has demonstrated potent and durable efficacy and a favorable safety profile in 3 phase III studies in treatment-naïve and treatment-experienced patients with HIV-1 infection. This manuscript provides a...